The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 70 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
FOCL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FOCL's RSI Indicator exited the oversold zone, 28 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.608) is normal, around the industry mean (14.423). P/E Ratio (-3.192) is within average values for comparable stocks, (11.188). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FOCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 29 cases where STXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 66 cases where STXS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for STXS just turned positive on November 18, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Following a +14.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 78 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
FOCL | STXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 80 | |
P/E GROWTH RATING 1..100 | 13 | 18 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FOCL's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for STXS (94) in the Medical Specialties industry. This means that FOCL’s stock grew somewhat faster than STXS’s over the last 12 months.
FOCL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.
FOCL's SMR Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.
FOCL's Price Growth Rating (65) in the Biotechnology industry is in the same range as STXS (80) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.
FOCL's P/E Growth Rating (13) in the Biotechnology industry is in the same range as STXS (18) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.
| FOCL | STXS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 1 day ago 83% |
| Stochastic ODDS (%) | 2 days ago 77% | 1 day ago 76% |
| Momentum ODDS (%) | 2 days ago 77% | 1 day ago 75% |
| MACD ODDS (%) | 2 days ago 85% | 1 day ago 80% |
| TrendWeek ODDS (%) | 2 days ago 84% | 1 day ago 82% |
| TrendMonth ODDS (%) | 2 days ago 85% | 1 day ago 79% |
| Advances ODDS (%) | 18 days ago 76% | 1 day ago 75% |
| Declines ODDS (%) | 3 days ago 84% | 4 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 75% | 1 day ago 86% |
| Aroon ODDS (%) | 2 days ago 89% | 1 day ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FOCL’s FA Score shows that 1 FA rating(s) are green while STXS’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FOCL’s TA Score shows that 4 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).
FOCL (@Medical Distributors) experienced а -12.18% price change this week, while STXS (@Pharmaceuticals: Other) price change was +5.12% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -12.67%. For the same industry, the average monthly price growth was -25.45%, and the average quarterly price growth was -27.62%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -4.88%. For the same industry, the average monthly price growth was -2.33%, and the average quarterly price growth was +6.73%.
STXS is expected to report earnings on Feb 26, 2027.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
@Pharmaceuticals: Other (-4.88% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To FOCL | 1D Price Change % | ||
|---|---|---|---|---|
| FOCL | 100% | -9.03% | ||
| AORT - FOCL | 29% Poorly correlated | -0.05% | ||
| UFPT - FOCL | 20% Poorly correlated | -2.20% | ||
| SENS - FOCL | 20% Poorly correlated | -8.57% | ||
| STXS - FOCL | 16% Poorly correlated | +6.75% | ||
| ACH - FOCL | 16% Poorly correlated | N/A | ||
More | ||||
A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.
| Ticker / NAME | Correlation To STXS | 1D Price Change % | ||
|---|---|---|---|---|
| STXS | 100% | +6.75% | ||
| SMTI - STXS | 38% Loosely correlated | -0.18% | ||
| TWST - STXS | 36% Loosely correlated | -4.07% | ||
| CERS - STXS | 35% Loosely correlated | -2.06% | ||
| VCYT - STXS | 33% Poorly correlated | -2.07% | ||
| SHC - STXS | 32% Poorly correlated | -0.43% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AELV | 26.22 | N/A | N/A |
| Harbor AlphaEdge Large Cap Value ETF (AELV) | |||
| FMB | 49.24 | -0.08 | -0.16% |
| First Trust Managed Municipal ETF (FMB) | |||
| MARM | 34.50 | -0.09 | -0.26% |
| FT Vest U.S. Equity Max Buffer ETF - March (MARM) | |||
| EMF | 18.62 | -0.32 | -1.69% |
| Templeton Emerging Markets Fund | |||
| FDNI | 23.41 | -0.54 | -2.27% |
| First Trust Dow Jones International Internet ETF (FDNI) | |||